| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.6 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.6 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |